STEERlife and Callidus Research Laboratories have recently announced a collaboration aimed at speeding up the process of drug development for global markets. By combining STEERlife’s advanced hot melt extrusion and continuous processing technologies with Callidus’ expertise in pharmaceutical drug development, the partnership is set to address the increasing demand for innovative drug formulations and development worldwide.
This collaboration not only allows both companies to leverage their specialized knowledge and skills but also paves the way for the creation of groundbreaking solutions and improved product offerings. Through this partnership, end-to-end drug development for active pharmaceutical ingredients (APIs) becomes possible.
STEERlife CEO, Indu Bhushan, emphasized that this collaboration will provide clients with access to cutting-edge technologies, extensive product development expertise, and seamless scale-up capabilities. On the other hand, Vardhaman Bafna, Co-founder, and Director of Callidus Research Laboratories, highlighted the alliance’s commitment to pushing boundaries, fostering growth, and enhancing patient outcomes through transformative pharmaceutical solutions.
The partnership between STEERlife and Callidus Research Laboratories signals a significant step forward in the field of drug development. By combining their respective strengths, these two companies are poised to revolutionize the way new drugs are formulated and brought to market, ultimately benefiting patients around the world.
In today’s rapidly evolving pharmaceutical landscape, collaborations like this are essential for driving innovation and meeting the growing needs of global markets. As technology continues to advance and consumer expectations rise, partnerships between industry leaders will play a crucial role in shaping the future of healthcare and pharmaceuticals.
Overall, the collaboration between STEERlife and Callidus Research Laboratories represents a promising development in the quest to optimize drug development processes. By pooling their resources and expertise, these two companies are well-positioned to lead the way in creating groundbreaking pharmaceutical solutions that have the potential to improve countless lives.
